Remove tag value-based-models
article thumbnail

Grand Rounds October 13, 2023: Incorporating Social Determinants of Health Into PCORnet (Keith Marsolo, PhD)

Rethinking Clinical Trials

Speaker Keith Marsolo, PhD Associate Professor Department of Population Health Sciences Duke University School of Medicine Slides Keywords PCORnet, Common Data Model, EHR, Social Determinants of Health Key Points There are many different definitions of social determinants of health. There was a wide spread of information that was available.

article thumbnail

Grand Rounds May 5, 2023: All of Us Research Program: Improving Health Through Diverse Technology, Huge Cohorts, and Precision Medicine (Joshua C. Denny, MD, MS)

Rethinking Clinical Trials

Returning value is a key part of the program. The Researcher Workbench is a cloud-based central resource with a passport access model. We want trials to adhere to our core values and have the data come back to our ecosystem. More than 631,000 participants have enrolled in All of Us with continued growth.

Medicine 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds June 16, 2023: BeatPain Utah: Partnering With Community Health Centers Within a Socio-Technical Framework (Julie Fritz, PT, PhD, FAPTA; Guilherme Del Fiol, MD, PhD)

Rethinking Clinical Trials

Clinical research can exacerbate disparities, because clinical trials typically are based in urban, academic medical centers, underrepresent diverse populations, and overlook community engagement strategies in trial planning and design.

article thumbnail

Grand Rounds November 3, 2023: The Perils and Pitfalls of Complex Clustering in Pragmatic Trials (Jonathan Moyer, PhD; Moderator: Andrea Cook, PhD)

Rethinking Clinical Trials

Expressions for ICC are more complicated with multiple membership structures, since the value of each ICC depends on the agent weights for ICCs found for pairs of agents. For nested models, the analytic model should match the expected structure of the data, and naïve models should not be used.

Trials 130
article thumbnail

Grand Rounds July 7, 2023: Implementing Virtual Strategies Across an Integrated Healthcare System: The IMPLEMENT-HF Study (Ankeet S. Bhatt, MD, MBA, ScM)

Rethinking Clinical Trials

In modeling exercises, optimal implementation of these therapies, such as an ARNI, a beta blocker, an MRA, and an SGLT2 inhibitor, compared to conventional therapy (an ACEi or ARB plus a beta blocker) is estimated to afford more than 6 years of survival in a typical 55-year-old patient. Would this provide incremental value?

article thumbnail

What challenges does the advanced therapies sector face? 

Drug Discovery World

He said: “The industry, as a whole, needs to carefully consider the true value of curing lifelong genetic or degenerative diseases, particularly when evaluating novel therapeutics that present unique treatment opportunities.” Developing value-based payment models that consider long-term benefits could improve access.

article thumbnail

Grand Rounds August 25, 2023: Pragmatic Trial of an EHR Application to Display Real-time PRO Data: Successes and Challenges (Gabriela Schmajuk, MD, MS)

Rethinking Clinical Trials

The treatment philosophy for RA is to treat-to-target based on PRO disease activity scores. The trial team also did a qualitative analysis with the clinicians and analyzed according to the technology acceptance model. These outcomes include disease activity, function status, and pain score.

Trials 141